At the time of writing, Pyxis Oncology Inc [PYXS] stock is trading at $2.21, up 7.80%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The PYXS shares have gain 18.18% over the last week, with a monthly amount glided 78.23%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Pyxis Oncology Inc [NASDAQ: PYXS] stock has seen the most recent analyst activity on September 04, 2025, when Guggenheim initiated its Buy rating and assigned the stock a price target of $5. Previously, William Blair downgraded its rating to Mkt Perform on November 21, 2024. On November 08, 2024, Stephens initiated with a Overweight rating and assigned a price target of $13 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $10 on August 08, 2024. BTIG Research started tracking with a Buy rating for this stock on February 09, 2024, and assigned it a price target of $8. In a note dated January 23, 2024, Leerink Partners initiated an Outperform rating and provided a target price of $12 on this stock.
For the past year, the stock price of Pyxis Oncology Inc fluctuated between $0.83 and $5.39. Currently, Wall Street analysts expect the stock to reach $5 within the next 12 months. Pyxis Oncology Inc [NASDAQ: PYXS] shares were valued at $2.21 at the most recent close of the market. An investor can expect a potential return of 126.24% based on the average PYXS price forecast.
Analyzing the PYXS fundamentals
Gross Profit Margin for this corporation currently stands at 0.52% with Operating Profit Margin at -17.11%, Pretax Profit Margin comes in at -15.78%, and Net Profit Margin reading is -15.48%. To continue investigating profitability, this company’s Return on Assets is posted at -0.78, Equity is -0.83 and Total Capital is -1.01. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.22.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Pyxis Oncology Inc [NASDAQ:PYXS] has a current ratio of 5.65. Further, the Quick Ratio stands at 5.65, while the Cash Ratio is 0.61. Considering the valuation of this stock, the price to sales ratio is 48.60, the price to book ratio is 1.56.
Transactions by insiders
Recent insider trading involved HUMPHREY RACHEL, Director, that happened on Apr 21 ’25 when 13896.0 shares were purchased. Director, HUMPHREY RACHEL completed a deal on Apr 17 ’25 to buy 200.0 shares. Meanwhile, Director HUMPHREY RACHEL bought 1400.0 shares on Apr 14 ’25.
